On Tuesday, ARS Pharmaceuticals Inc (NASDAQ: SPRY) opened higher 0.07% from the last session, before settling in for the closing price of $13.78. Price fluctuations for SPRY have ranged from $4.64 to $18.51 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -34.76% annually for the last half of the decade. Company’s average yearly earnings per share was noted 12.72% at the time writing. With a float of $50.64 million, this company’s outstanding shares have now reached $96.41 million.
In an organization with 26 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 96.05%, operating margin of -5829.09%, and the pretax margin is -4730.64%.
ARS Pharmaceuticals Inc (SPRY) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of ARS Pharmaceuticals Inc is 47.89%, while institutional ownership is 42.07%. The most recent insider transaction that took place on Nov 15 ’24, was worth 4,089,374. Before that another transaction happened on Nov 12 ’24, when Company’s CHIEF MEDICAL OFFICER sold 100,000 for $16.85, making the entire transaction worth $1,684,642. This insider now owns 1,248,499 shares in total.
ARS Pharmaceuticals Inc (SPRY) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 12.72% per share during the next fiscal year.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Trading Performance Indicators
Check out the current performance indicators for ARS Pharmaceuticals Inc (SPRY). In the past quarter, the stock posted a quick ratio of 12.50. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 521.48.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.51, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.41 in one year’s time.
Technical Analysis of ARS Pharmaceuticals Inc (SPRY)
Let’s dig in a bit further. During the last 5-days, its volume was 1.75 million. That was better than the volume of 0.81 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 9.71%. Additionally, its Average True Range was 1.10.
During the past 100 days, ARS Pharmaceuticals Inc’s (SPRY) raw stochastic average was set at 53.54%, which indicates a significant increase from 8.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 82.19% in the past 14 days, which was higher than the 72.11% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.72, while its 200-day Moving Average is $10.86. However, in the short run, ARS Pharmaceuticals Inc’s stock first resistance to watch stands at $14.21. Second resistance stands at $14.64. The third major resistance level sits at $14.99. If the price goes on to break the first support level at $13.43, it is likely to go to the next support level at $13.08. The third support level lies at $12.65 if the price breaches the second support level.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Key Stats
There are currently 97,185K shares outstanding in the company with a market cap of 1.34 billion. Presently, the company’s annual sales total 30 K according to its annual income of -54,370 K. Last quarter, the company’s sales amounted to 2,070 K and its income totaled -19,130 K.
